Estudio de patritumab deruxtecan más pembrolizumab con otros agentes anticancerígenos en participantes con cáncer de mama triple negativo o hormonal de alto riesgo de alto riesgo o receptor-bajo positivo/HER-2 negativo (MK-1022-010, Herthena-Brast-03)
Un estudio de fase 2 aleatorizado abierto para evaluar la seguridad y la eficacia de patritumab deruxtecan más pembrolizumab administrado antes o después de carboplatino/paclitaxel más pembrolizumab en comparación con pembrolizumab en combinación con quimioterapia seguida de cirugía y pembrolizumab adyuvante para un triple temprano de alto nivel en el ridículo-estado temprano- Receptor negativo o hormonal-bajo positivo/factor de crecimiento epidérmico humano receptor-2 cáncer de mama negativo (Hertena-Brast03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:
- About the safety of the study treatments and if people tolerate them
- If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Toll Free Number
- Número de teléfono: 1-888-577-8839
- Correo electrónico: Trialsites@msd.com
Ubicaciones de estudio
-
-
-
Seoul, Corea del Sur, 03080
- Reclutamiento
- Seoul National University Hospital ( Site 2400)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82220720850
-
Seoul, Corea del Sur, 05505
- Reclutamiento
- Asan Medical Center ( Site 2401)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82230103217
-
Seoul, Corea del Sur, 03722
- Reclutamiento
- Severance Hospital, Yonsei University Health System ( Site 2402)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82222288135
-
-
-
-
-
Córdoba, España, 14004
- Reclutamiento
- Hospital Universitario Reina Sofia ( Site 1702)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34 957012408
-
-
Catalonia
-
Badalona, Catalonia, España, 08916
- Reclutamiento
- Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34934978925
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, España, 28027
- Reclutamiento
- Clinica Universidad de Navarra ( Site 1703)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34913531920
-
-
-
-
California
-
Santa Monica, California, Estados Unidos, 90404
- Reclutamiento
- UCLA Hematology/Oncology - Parkside ( Site 0021)
-
Contacto:
- Study Coordinator
- Número de teléfono: 424-402-9520
-
-
Illinois
-
Skokie, Illinois, Estados Unidos, 60077
- Reclutamiento
- Orchard Healthcare Research Inc. ( Site 0006)
-
Contacto:
- Study Coordinator
- Número de teléfono: 847-568-9932
-
-
Montana
-
Billings, Montana, Estados Unidos, 59102
- Reclutamiento
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
-
Contacto:
- Study Coordinator
- Número de teléfono: 406-238-6685
-
-
Oregon
-
Happy Valley, Oregon, Estados Unidos, 97015
- Reclutamiento
- Northwest Cancer Specialists, P.C. ( Site 8003)
-
Contacto:
- Study Coordinator
- Número de teléfono: 360-944-9889
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- SCRI Oncology Partners ( Site 7000)
-
Contacto:
- Study Coordinator
- Número de teléfono: 844-482-4812
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- Reclutamiento
- Texas Oncology - DFW ( Site 8000)
-
Contacto:
- Study Coordinator
- Número de teléfono: 214-370-1067
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Houston Methodist Hospital ( Site 0022)
-
Contacto:
- Study Coordinator
- Número de teléfono: 713-441-9948
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 23502
- Reclutamiento
- Virginia Oncology Associates (VOA) ( Site 8001)
-
Contacto:
- Study Coordinator
- Número de teléfono: 844-482-4812
-
-
-
-
-
Taichung, Taiwán, 407
- Reclutamiento
- Taichung Veterans General Hospital ( Site 2502)
-
Contacto:
- Study Coordinator
- Número de teléfono: +886423592525
-
Tainan, Taiwán, 704
- Reclutamiento
- National Cheng Kung University Hospital ( Site 2503)
-
Contacto:
- Study Coordinator
- Número de teléfono: +88662353535
-
Taipei, Taiwán, 112
- Reclutamiento
- Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
-
Contacto:
- Study Coordinator
- Número de teléfono: 886228970011x1686
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
- Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
- Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has uncontrolled or significant cardiovascular disease before randomization
- Has any history of or evidence of any current leptomeningeal carcinomatosis.
- Has clinically significant corneal disease
- Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
- Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
- Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
- Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
- Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
- Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
- Has known additional malignancy that is progressing or has required active treatment within the past 5 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
- Has an active infection requiring systemic therapy
- Has concurrent active HBV and HCV infection
- Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. |
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
|
|
Experimental: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Otros nombres:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Otros nombres:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Otros nombres:
|
|
Experimental: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Otros nombres:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Otros nombres:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Otros nombres:
|
|
Comparador activo: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles. |
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Otros nombres:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Otros nombres:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Otros nombres:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1: Number of Participants Experiencing an Adverse Event (AE)
Periodo de tiempo: Up to ~43 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1. |
Up to ~43 weeks
|
|
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Periodo de tiempo: Up to 21 days
|
A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity. |
Up to 21 days
|
|
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
Periodo de tiempo: Up to ~30 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1. |
Up to ~30 weeks
|
|
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Periodo de tiempo: Up to ~30 weeks
|
pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Number of Participants Experiencing an AE
Periodo de tiempo: Up to ~103 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2. |
Up to ~103 weeks
|
|
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Periodo de tiempo: Up to ~90 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2. |
Up to ~90 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
Periodo de tiempo: Up to ~30 weeks
|
pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Event-Free Survival (EFS)
Periodo de tiempo: Up to ~100 months
|
EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Overall Survival (OS)
Periodo de tiempo: Up to ~100 months
|
OS is defined as the time from randomization to date of death due to any cause. |
Up to ~100 months
|
|
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
Periodo de tiempo: Up to ~100 months
|
DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Residual Cancer Burden (RCB)
Periodo de tiempo: Up to ~30 weeks
|
RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28). |
Up to ~30 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Director de estudio: Medical Director, Merck Sharp & Dohme LLC
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades de la piel
- Enfermedades de los senos
- Enfermedades de la piel y del tejido conectivo
- Neoplasias de mama
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Ácidos nucleicos, nucleótidos y nucleósidos
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Carbohidratos
- Hidrocarburos aromáticos policíclicos
- Hidrocarburos, aromáticos
- Compuestos policíclicos
- Glucósidos
- Complejos de coordinación
- Taxaides
- Ciclodecanos
- Diterpenos
- Desoxicitidina
- Citidina
- Nucleósidos de pirimidina
- Pirimidinas
- Mostaza de fosforamida
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Fosforamidas
- Compuestos organofosforados
- Nucleósidos
- Uracílico
- Pirimidinonas
- Antraciclinas
- Naftacenos
- Aminoglucósidos
- Daunorrubicina
- Desoxirribonucleósidos
- Fluorouracil
- Capecitabina
- Ciclofosfamida
- Carboplatino
- Doxorrubicina
- Paclitaxel
- Epirrubicina
- pembrolizumab
- olaparib
- Patritumab deruxtecan
Otros números de identificación del estudio
Otros números de identificación del estudio
- 1022-010
- MK-1022-010 (Otro identificador: MSD)
- U1111-1307-7867 (Identificador de registro: UTN)
- 2024-514376-40-00 (Identificador de registro: EU CT)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .